Why Drug Developers Choose IgG4 for Monoclonal Antibodies? – Illiasul Ibad
Illiasul Ibad, Rheumatologist at Christian Medical College, posted on X:
”1․ Why are many therapeutic monoclonal antibodies built on the IgG4 framework?
2․ Understand basics
Biology of IgG4
• Least abundant IgG subclass
• Very weak complement activation
• Poor interaction with Fc receptors → almost no ADCC
Translation: IgG4 can block targets without collateral tissue damage.
3․ Fab-arm exchange
Natural IgG4 can swap half its arms → becomes “functionally monovalent.”
Good for tolerance in nature, but bad for drug stability.
Solution: scientists engineered the S228P mutation → no swapping, molecule stays stable.
4․ Why drug developers love IgG4
• Precise blocking, not killing
• Low inflammation risk
• Engineered stability
• Safe for long-term therapy
That’s why IgG4 is the backbone of modern antibody medicines – quiet, stable, effective.”
Stay updated with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026